-
Shanghai Municipal Public Health Clinical Center completed the clinical study of PD-L1 antibody ASC22 (envorizumab) combined with sidabenamide for functional cure of HIV infection
Time of Update: 2022-10-03
The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy of ASC22 (envorizumab) plus cedabenamide in HIV-infected people on infected incubation cell virus reservoirs.
The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy of ASC22 (envorizumab) plus cedabenamide in HIV-infected people on infected incubation cell virus reservoirs.
-
Corning Jerry HER2 Dual Anti-Conjugated Drug (KN026-ADC) JSKN003 completed the first patient administration in a phase I clinical study in Australia
Time of Update: 2022-10-02
HK) announced that the company's self-developed HER2 bispecific antibody conjugated drug (KN026-ADC, R&D code: JSKN003) in Australia to treat advanced solid tumors Phase I clinical research completed the first patient administration.
-
Deservedly, the honor was on the list - Kexing Pharmaceutical Changle Kang was awarded the "2021~2022 Chinese Family"
Time of Update: 2022-10-02
(hereinafter referred to as "Kexing Pharmaceutical", stock code: 688136) were honored to be on the list with its excellent product quality and winning reputation!After layers of selection and fierce competition, on September 19, the list of "2021-2022 China Family Standing Health Products Listed Brands" was announced, and the probiotic products Changlekang (Clostridium butyric acid bifieria) of Kexing Biopharmaceutical Co.
-
The National Institute for Health and Clinical Excellence recommends Baiyueze? (Zebutinib) is used to treat patients with Fahrenheit macroglobulinemia who have previously received at least one treatment
Time of Update: 2022-10-02
NICE's positive recommendation to Beaux-Benz ® will help patients in England and Wales who meet the treatment criteria have this important new treatment option that delivers better outcomes than current standard treatments.
-
Shanghai Pharmaceutical strengthens innovation and research and development to promote the high-quality development of the biomedical industry
Time of Update: 2022-09-30
Recently, when Shanghai Pharmaceutical was surveyed by investors, it said that the company's clinical applications have been accepted and entered the clinical research stage of the new drug pipeline
-
Good news! Shandong Dingxin was elected as a director unit of the Professional Committee of Chinese Herbal Medicine Processing Equipment
Time of Update: 2022-09-30
As a professional manufacturer in the field of shredding equipment, Shandong Dingxin has always focused on the innovation and breakthrough of shredding technology, continuously improving the crushing efficiency and crushing capacity of pulverizer equipment, and providing strong equipment and technical support for traditional Chinese medicine and other industries.
-
600 million yuan! The leading API company has greatly expanded its production capacity
Time of Update: 2022-09-30
The company intends to use its own funds to invest 600 million yuan in a new API production base project in Zhongxiang City, Hubei Province.
The company intends to use its own funds to invest 600 million yuan in a new API production base project in Zhongxiang City, Hubei Province.
-
Innovent Biologics PD-1/IL-2 bispecific antibody fusion protein IBI363 completed the first clinical patient administration in Australia
Time of Update: 2022-09-24
” Cinda Biopharmaceutical Group (HKEx Stock Code: 01801), a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs in the field of oncology, self-immunity, metabolism, ophthalmology and other major diseases, Today announced the completion of its self-developed recombinant anti-programmed death receptor 1 (PD-1) antibody fusion interleukin 2 (IL-2) bispecific molecule (R&D code: IBI363) in a Phase I clinical trial in Australia for the treatment of advanced solid tumors or lymphomas.
-
BIOSET has entered into a collaboration with Bonn Biotech on the development of cell therapy drugs based on TCR-like antibodies
Time of Update: 2022-09-21
On September 8, 2022, BIOSAITU (Beijing) Pharmaceutical Technology Co. , Ltd. (hereinafter referred to as "BIOSAITU", stock code: 02315. HK) announced that it has entered into a cooperation agreement
-
Sino-Cheng Jianhua announced the completion of the first patient administration in China in the Tafasitamab combined with lenalidomide for relapse/refractory DLBCL Phase II registered clinical trials
Time of Update: 2022-09-21
Sino-Cheng Jianhua (HKEx: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) adult patients who are not suitable for autologous stem cell transplantation (ASCT) has completed phase II registered clinical trial (registration number: CTR20221519) in China.
-
Innovent BioORIENT-31 studies that sindilizumab combined with chemotherapy in EGFR mutant non-squamous non-small cell lung cancer obtained a significant prolongation of PFS
Time of Update: 2022-09-21
Orient-31 studies have shown that sindilizumab immunotherapy combined with chemotherapy has a PFS benefit in EGFR-TKI-resistant NSCLC patients compared with standard platinum-containing chemotherapy, confirming the value of immunotherapy in this population, and this combination therapy regimen is also expected to become one of the treatment options for patients with EGFR-TKI-TKI resistant NSCLC, bringing more benefits to patients.
-
The Chinese team discovered a new method for safe induction of pluripotent stem cells, which accelerates cell differentiation based on surface acoustic waves
Time of Update: 2022-09-20
New methods for the safe induction of pluripotent stem cells have been "cracked". Recently, Yang Xin's team from Cardiff University in the United Kingdom and Wuhan Ruijian Pharmaceutical team publish
-
Key physicochemical property considerations in the early development of new drugs - permeability prediction
Time of Update: 2022-09-20
The industry usually combines parallel artificial membrane permeation technology (PAMPA) and Caco-2 cell model as permeability prediction methods in the early stage of drug development, and the current Ussing chamber rat model is also widely used for its absorption window evaluation advantages.
-
Dry! The development of fiery small nucleic acid drugs, those technical points that are difficult to break through
Time of Update: 2022-09-20
Small nucleic acid drugs are an area of great attention to new drug research and development in recent years, and with their unique technical characteristics, they provide an important research direction to meet the unmet clinical needs, especially for the field of rare diseases with a large number.
-
Nature The full field of view of the human immune system is a map of each other
Time of Update: 2022-09-20
So the researchers sought to contextualize the interactions of the network by creating an interactive atlas that plots the locations of these receptor and ligand pairs detected in a single-cell expression dataset of human tissues.
-
Data on premenopausal patients in the second-generation breast cancer polygenic test EndoPredict were officially released at the CCR
Time of Update: 2022-09-14
Dr. Anastasia Constantinidou et al. published a new study, Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, in clinical cancer research (CCR, impact factor IF=12. 531). ,
-
Invest $2.2 million! The pharmaceutical company will be in Singapore for another city
Time of Update: 2022-09-14
Publicly available, Catalent is a company dedicated to delivering technology, development and manufacturing solutions for pharmaceuticals, biologics, cell and gene therapies, and consumer health products, with four divisions, including SoftGel and Oral Technologies, Biologics, Oral and Specialist Delivery, and Clinical Supply Services.
-
Laikai Pharmaceuticals LAE201INT2101 Clinical Phase I/II study completed the first subject administration in Korea
Time of Update: 2022-09-14
LAE201INT2101 is a multicenter, open-label Phase I/II clinical study evaluating the safety and antitumor efficacy of LAE001+LAE002 (afuresertib) as a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) who have advanced or intolerated disease after standard treatment.
-
The PLUS KRAS G12C inhibitor completes the first patient administration of the STK11 co-mutant IIa trial
Time of Update: 2022-09-14
Dr. Yinxiang Wang, Chairman and CEO of Jiacosi, said: "JAB-21822 is the first and only drug in China that has been approved clinically for the first-line treatment of STK11 and KRAS G12C co-mutant non-small cell lung cancer.
-
2022 ESMO:DZD1516 International Multicenter Breast Cancer Clinical Study Results Positive
Time of Update: 2022-09-14
Based on the unique tumor central nervous system metastasis research platform, Di Zhe designed and developed DZD1516, a highly selective HER2 inhibitor with the ability to fully penetrate the blood-brain barrier.
